KUALA LUMPUR, Malaysia, June 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq:ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced its expansion into patient-derived organoid (PDO) technology through a Research and Collaboration Agreement with Dr. Kong Wai Mun, Executive Director of Axiocell Biotech and a biomedical scientist with more than 17 years of experience in translational research and preclinical model development.
Read more at globenewswire.comThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/A%20close-up%20shot%20of%20a%20Broadcom%20chip%20by%20g0d4ather%20via%20Adobe%20Stock.jpeg)
/A%20close-up%20of%20a%20SpaceX%20sign%20by%20Sundry%20Photography%20via%20Adobe%20Stock.jpeg)
/Apple%20logo%20-%20by%20Pexels%20via%20Pixabay.jpg)